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Identification of early inflammatory genes involved in adenosine
signaling using a pharmacogenomics approach
Abstract
Adenosine is a paradoxical inflammatory modulator. It can both participate in inflammatory shutdown
and also mediate the persistence of inflammation, by activating different adenosine receptors (AR).
Here, a pharmacogenomics approach was employed to identify AR sub-type specific cellular signals in
the human mast cell-line 1 (HMC-1). Two gene products previously not associated to adenosine
signaling were further characterized. First, we determined that AR activation results in upreguation and
secretion of macrophage inflammatory protein-1 beta (MIP-1β) into the cell culture medium, suggesting
a mechanism by which adenosine can modulate chemotaxis by mast cells. Second, we detected a sharp
upregulation of the inflammatory transcription factors NR4A2 and NR4A3, accompanied by an increase
in their transcriptional activity. Notably, this effect appears to be mediated by A2BAR and A3AR, while
A2AAR activation counteracted NR4A2 and NR4A3 induction by other ARs. Furthermore, while
non-selective AR activation strongly potentiated PMA/I-mediated induction of NR4As, selective
A2AAR engagement partially revoked it, indicating that A2AAR modulatory effect is conserved to
other pro-inflammatory stimuli. Overall, these findings show that AR activation can have broad
regulatory effects on human mast cells, not only by a direct effect on inflammation-associated factors,
but also by influencing the recruitment of inflammatory cells through chemotactic cytokines.
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List of abbreviations 
 
 
ADA  Adenosine deaminase 
AMP  Adenosine monohosphate 
ATP  Adenosine triphosphate 
AR  Adenosine receptor 
BAL  Bronchoalveolar lavage 
BSA  Bovine Serum Albumin 
cAMP  Cyclic adenosine monophosphate 
CGS-21680 9-Chloro-2-(2-furanyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine 
CNS  Central nervous system 
CREM cAMP response element modulator 
Ct  Threshold cycle  
KD  Kilo Dalton 
DAPI  4’,6-Diamidino-2-phenylindole 
DMSO Dimethyl sulfoxide 
DNA  Desoxyribonucleic acid 
cDNA  Complementary DNA 
ELISA  Enzyme-Linked ImmunoSorbent Assay 
FBS  Foetal bovine serum 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GPCR  G protein-coupled receptors 
HMC-1 Human mast cell line 1 
IB-Meca 1-Deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-y l]-N 
  methyl-b-D-ribofuranuronamide 
IgE  Immunoglobulin E 
IL  Interleukin 
IMDM  Iscove's Modified Dulbecco's Medium 
LPS  Bacterial lipopolysaccharide 
LUC  Luciferase, firefly luciferase 
MAPKs Mitogen-activated protein kinase/s 
MC  Mast cell 
MCP-1 Monocyte chemoattractant protein 1  
MIP-1β  Macrophage Inflammatory Protein-1 beta 
NBRE  Nerve-growth factor responsive element 
NECA  5′-N-Ethylcarboxamido-adenosine 
NK  Natural killer cells 
NR4A  Nuclear orphan receptor 4 A 
PAGE  Polyacrylamide gel electrophoresis 
PBS  Phosphate-buffered saline 
PKA  Protein kinase A 
PLC   Phospholipase C 
PMA  Phorbol 12-myristate 13-acetate 
RNA  Ribonucleic acid 
mRNA Messenger RNA 
Rpm  Revolution per minute 
RT-PCR Reverse transcriptase polymerase chain reaction 
SCH-58261 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4- 
  triazolo[1,5-c]pyrimidine) 
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SDS  Sodium dodecyl sulfate 
SEM  Standard error of the mean 
TBS  Tris-buffered saline 
TBST  Tris-buffered saline Tween 20 
TLR4   Toll-like receptor 4 
UT  Untreated 
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Summary  
 
Adenosine is a paradoxical inflammatory modulator. It can both participate in 
inflammatory shutdown and also mediate the persistence of inflammation, by 
activating different adenosine receptors (AR). Here, a pharmacogenomics 
approach was employed to identify AR sub-type specific cellular signals in the 
human mast cell-line 1 (HMC-1). Two gene products previously not 
associated to adenosine signaling were further characterized. First, we 
determined that AR activation results in upreguation and secretion of 
macrophage inflammatory protein-1 beta (MIP-1β) into the cell culture 
medium, suggesting a mechanism by which adenosine can modulate 
chemotaxis by mast cells. Second, we detected a sharp upregulation of the 
inflammatory transcription factors NR4A2 and NR4A3, accompanied by an 
increase in their transcriptional activity. Notably, this effect appears to be 
mediated by A2BAR and A3AR, while A2AAR activation counteracted NR4A2 
and NR4A3 induction by other ARs. Furthermore, while non-selective AR 
activation strongly potentiated PMA/I-mediated induction of NR4As, selective 
A2AAR engagement partially revoked it, indicating that A2AAR modulatory 
effect is conserved to other pro-inflammatory stimuli. Overall, these findings 
show that AR activation can have broad regulatory effects on human mast 
cells, not only by a direct effect on inflammation-associated factors, but also 
by influencing the recruitment of inflammatory cells through chemotactic 
cytokines. 
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Introduction 
General concepts 
Adenosine is an endogenous by-product normally present at low 
concentrations in the extracellular space. An increment in adenosine 
formation occurs as a result of hypoxia, tissue injury and acute or chronic 
inflammation. The rapid accumulation of adenosine is followed by a number of 
responses, which can be regarded as organ protective. On one hand, 
extracellular adenosine represents a pre-eminent alarm molecule that reports 
tissue injury in an autocrine and paracrine manner to surrounding tissue. On 
the other hand, it decreases tissue energy demand via a direct inhibitory 
effect on parenchymal cell function and by providing a more favorable cellular 
environment by increasing nutrient availability via vasodilatation (Linden, 
2001). In addition, adenosine helps to maintain tissue integrity by modulating 
the immune system and by regulating exuberant immune responses. During 
chronic inflammatory processes, however, the sustained formation of 
adenosine has been associated with deleterious effects. Elevated adenosine 
concentrations can be found, for example, in bronchoalveolar lavage (BAL) 
and exhaled breath condensate of human patients with asthma (Driver et al., 
1993;Huszar et al., 2002), where it perpetuates inflammation and contributes 
to airway hyperresponsiveness.  
Although the bioavailability of adenosine is an important determinant of its 
biological functions, the pattern of expression and distribution of its receptors 
in the anatomical–structural sites accounts for the observation that adenosine 
may exert either deleterious or protective roles. Each of the four adenosine 
receptors (AR) identified to date, A1, A2A, A2B and A3, has a unique 
pharmacological profile, tissue distribution and effector coupling. The 
characterization of each receptor subtype has stimulated the search for 
specific ligands able to modulate the effects of this molecule in a directed 
way. To date, several compounds of different chemical classes with great 
potential have been identified but side effects in several organs derived from 
the broad distribution of the receptors across the organism have prevented 
their clinical application.  
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Adenosine homeostasis  
Adenosine is composed of a molecule of adenine attached to a ribose sugar 
molecule (ribofuranose) moiety via a glycosidic bond. It derives as a by-
product of adenosine triphosphate (ATP) degradation during the cycle of 
energy generation, principally by the cleavage of adenosine monophosphate 
(AMP) by 5’-nucleotidases, both in the intracellular and extracellular 
compartments. Once in the extracellular space, adenosine binds to G-protein 
coupled adenosine receptors, activating alternate signaling cascades, which 
ultimately result in biological effects. In physiological conditions, the level of 
adenosine is kept low by its conversion to AMP by adenosine kinase (Arch 
and Newsholme, 1978) and it is also degraded to inosine and hypoxanthine 
by adenosine deaminase (Trams and Lauter, 1974).  
 
 
 
Fig 1. Adenosine metabolism. 
Inosine 
Adenosine 
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Endo-5’- 
Nucleotidase 
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In metabolically stressful conditions such as ischemia, sepsis and hypoxia, 
extracellular adenosine concentration increases in proportion to energy 
consumption, ATP degradation and AMP accumulation, reaching local 
concentrations of up to 30 µM – a 150-fold increase over basal levels (Van 
Belle et al., 1987).  
 
Biological functions of adenosine 
Different functions have been attributed to adenosine in different organs. In 
the central nervous system adenosine acts as a neuromodulator, integrating a 
wide variety of brain functions. It modulates CNS excitability and plays a role 
in mechanisms of seizure susceptibility (Pagonopoulou et al., 2006), sleep 
induction (Basheer et al., 2004), basal ganglia function (Schwarzschild et al., 
2006), pain perception (Sawynok and Liu, 2003), cerebral blood flow (Shi et 
al., 2008) and respiration (Lahiri et al., 2007). Consequently, dysfunction of 
the adenosine system is involved in pathologies ranging from epilepsy to 
neurodegenerative disorders and psychiatric conditions. Because this 
nucleoside can integrate and fine-tune glutamatergic and dopaminergic 
neurotransmission, adenosine-regulating agents have the potential to modify 
a wide range of downstream effects. In addition, adenosine receptors are 
inhibited by caffeine and other methylxanthines and provide a potential target 
for treatment of cerebral ischemia (Ribeiro, 2005), seizures (During and 
Spencer, 1992), pain, Parkinson’s disease (Schapira et al., 2006) and 
Huntington’s disease (Blum et al., 2003).  
Adenosine is a potent vasodilator in most vascular beds (with the exception of 
renal afferent arterioles and hepatic veins) and it is indicated for myocardial 
perfusion scintigraphy in humans. This nucleoside also shows marked 
angiogenic effects, which are mostly mediated by the induction of pro-
angiogenic factors such as basic fibroblast growth factor (bFGF) and vascular 
endothelial growth factor (VEGF). In addition, this nucleoside shows 
anthiarrythmic effects (reduction of both heart rate and contractility) and it is 
intravenously administered to restore normal heart rhythm in patients with 
paroxysmal supraventricular tachychardia. Adenosine also protects
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the myocardium (as well as other tissues) from hypoxia or ischaemia through 
preconditioning (recently reviewed by Das and Das, 2008).  
Extracellular adenosine in the kidney affects vascular and tubular functions. It 
shows a prominent glomerular filtration rate reducing effect, by activating 
A1AR on afferent arterioles (Hansen and Schnermann, 2003). In the deep 
cortex and medulla, adenosine-induced vasodilation contributes to minimize 
medullary injury during hypoxic episodes. AR activation can also inhibit the 
secretion of renin (Edlund et al., 1994). Adenosine-mediated prevention of 
ischemia-reperfusion injury in the kidney is a clinically relevant protective 
mechanism and the underlying molecular events are now starting to be 
elucidated.  
A role for adenosine in glucose and insulin metabolism has also been 
established. Activation of the A1AR has been associated with an increase in 
plasma insulin, increase in insulin sensitivity and glucose uptake (Dong et al., 
2001). Agonists for this AR subtype have been tested in human as adjuvant 
therapy in type 2 insulin resistant diabetes and resulted in improved 
tryacilglycerol levels and reduced fatty acid levels (Donnelly and Qu, 1998). 
 
 
Fig 2. Main AR-mediated effects on several systems 
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Adenosine has well described anti-inflammatory and tissue protective effects 
in situations such as ischemia-reperfusion injury and acute inflammation (Day 
et al., 2004). In chronic conditions such as asthma and chronic obstructive 
pulmonary disease adenosine can, however, play a pro-inflammatory and 
tissue-destructive role and contribute to remodeling of the airways (Blackburn, 
2003). These seemingly paradoxical effects can be explained by the 
activation of alternate ARs on inflammatory cells, which activate diverse 
signaling cascades and different effector pathways.    
 
Adenosine receptors and their role in inflammation 
The adenosine G-coupled receptors (GPCR) consist of a central core domain 
with seven transmembrane helices connected by three intracellular and three 
extracellular loops. Both transmembrane and extracellular regions of ARs 
form the ligand-binding pocket and several amino acids that contribute to the 
ligand-binding properties have been identified via mutagenesis (Moro et al., 
2006). 
The four distinct adenosine receptors, A1, A2A, A2B and A3 have been cloned 
in rodents, dog, sheep, cow and humans. Usually, more than one adenosine 
receptor is expressed in a single cell resulting in a composite pharmacological 
response. ARs are densely expressed on virtually all inflammatory cell types, 
including monocytes and macrophages (Hasko et al., 2007; Khoa et al., 
2006), dendritic cells (Panther et al., 2001), mast cells (Feoktistov and 
Biaggioni, 1995), neutrophils (Fortin et al., 2006), platelets (Gessi et al., 
2000), endothelial cells (Li et al., 1998), eosinophils (Kohno et al., 1996), 
epithelial cells (Sitaraman et al., 2001) and fibroblasts (Chan et al., 2006), as 
well as lymphocytes (Apasov et al., 2000), NK and NKT cells (Harish et al., 
2003;Lappas et al., 2006).  
 
A1AR 
This subclass of AR has been associated with both pro- and anti-inflammatory 
effects. On one hand, it has been shown that activation of A1 receptor can 
promote activation of human neutrophils and monocytes, thus leading to 
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proinflammatory responses (Merrill et al., 1997; Salmon et al., 1993). On the 
other, the genetic removal of the A1 receptor gene in adenosine deaminase-
deficient mice resulted in enhanced pulmonary inflammation, indicating that in 
this context the activation of A1AR serves an anti-inflammatory and/or 
protective role in the regulation of pulmonary disorders (Sun et al., 2005). A1 
receptors were also shown to play an anti-inflammatory and protective role in 
experimental models of injury in the heart, nerves and kidney (Lee et al., 
2004;Liao et al., 2003;Tsutsui et al., 2004). More recently, a role for A1AR in 
angiogenesis induction has been suggested (Clark et al., 2007). A1AR 
activation inhibits the adenylyl cyclase (Gi-mediated). Other pathways 
involved include protein kinase C (PKC), phosphoinositide 3 (PI3) kinase and 
mitogen-activated protein (MAP) kinases (reviewed by Jacobson and Gao, 
2006).  
 
A2AAR 
A2AAR receptors are widely distributed in the body. High expression of 
adenosine A2A mRNA has been found in leukocytes and platelets and in some 
areas of the central nervous system, while intermediate levels have been 
found in lung and heart (Fredholm et al., 2001). A2AAR are co-expressed with 
A2BAR in human mast cells found in bronchoalveolar lavage (Feoktistov and 
Biaggioni, 1998; Suzuki et al., 1998). Several lines of evidence suggest that in 
the lung A2AAR activate a protective mechanism playing a critical role in the 
down-regulation of inflammation and tissue damage in different models (Ohta 
and Sitkovsky, 2001; Thiel et al., 2005). Activation of A2A receptors seems to 
affect multiple aspects of the inflammatory process, modulating neutrophil 
activation and degranulation, oxidative species production, adhesion 
molecules expression, cytokine release and mast cell degranulation (Lappas 
et al., 2005). Therefore, it is not surprising that selective adenosine A2AAR 
agonists may hold potential in the pharmacological control of airway 
inflammation and inflammation-mediated lung tissue injury.  
A2AAR signal mainly by activation of the adenylate cyclase (cAMP), protein 
kinase A (PKA) canonical pathway, but they can also signal through the 
activation of an exchange factor that is directly activated by cAMP (Epac) 
(Fredholm et al., 2007). 
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A2BAR 
Functional human A2BARs have been identified in the smooth muscle cells 
(Zhong et al., 2004), lung fibroblasts (Zhong et al., 2005), endothelial cells 
(Feoktistov et al., 2002), bronchial epithelium (Clancy et al., 1999), and mast 
cells (Feoktistov and Biaggioni, 1998). A2BAR is a low-affinity receptor, 
requiring higher concentrations of adenosine to be significantly activated. 
Engagement of this receptor subtype has been associated to pro-
inflammatory biological events, including vasodilation (Martin, 1992), 
facilitation of antigen-induced degranulation in human mast-cells (Feoktistov 
and Biaggioni, 1995) and increased release of interleukin-6 and monocyte 
chemoattractant protein 1 (MCP-1) from epithelial cells, astrocytes and 
fibroblasts (Sitaraman et al., 2001; Zhong et al., 2005). Also, A2BAR signalling 
in the human mast cell line HMC-1 augments interleukin-8 (IL-8) release, 
upregulates Th2 cytokines (IL-4 and IL-13) and promotes IgE synthesis by B 
lymphocytes (Ryzhov et al., 2004). Also, ADA-/- mice treated with the A2B 
antagonist CVT-6883 showed less pulmonary inflammation, fibrosis, and 
alveolar airspace enlargement than controls (Sun et al., 2006). The A2BAR 
couples both to Gs, promoting cAMP accumulation, and to Gq triggering Ca
2+ 
mobilization and activation of PLC and MAPKs (Gao et al., 1999); the 
arachidonic acid pathway has also been implicated in A2B signaling (Donoso 
et al., 2005). Interestinlgy, crosstalk between Gs and Gq appears to regulate 
IL-4 production by A2B in human mast cells (Ryzhov et al., 2006).  
 
A3AR 
In humans, a relatively high density of functionally active A3ARs can be found 
in eosinophils and elevated transcript levels of this AR have been detected in 
lung biopsies of patients with asthma and in activated lymphocytes (Gessi et 
al., 2004). The functional role of this AR subtype remains controversial, mainly 
due to interspecies differences. In rats, mast cell degranulation seems to be 
dependent on A3AR activation (Fozard et al., 1996; Shepherd et al., 1996) 
and A3 receptor antagonism attenuates pulmonary inflammation, reduces 
eosinophil infiltration and decreases airway mucus production (Young et al., 
2004). In contrast, activation of these receptors by the A3AR specific agonist 
IB-MECA in humans inhibits eosinophil chemotaxis and other proinflammatory 
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functions (Walker et al., 1997). In addition, this compound induces anti-
inflammatory effects in experimental animal models of collagen- and adjuvant-
induced arthritis. In this context a combined therapy of A3AR agonist and 
methotrexate in adjuvant-induced arthritis in rats yielded an additive anti-
inflammatory effect (Ochaion et al., 2006). New and more potent A3AR 
agonists are currently being developed, some of which are already in clinical 
trials for the treatment of rheumatoid arthritis (Silverman et al., 2008). The 
signaling pathway associated with A3AR activation comprises Gi-mediated 
inhibition of adenyly cyclase and Gq-mediated stimulation of PLC (Gessi et al., 
2004). 
 
 
Adenosine signaling in lung inflammatory conditions  
Several findings suggest that adenosine plays a critical role in the 
pathogenesis of chronic inflammatory disorders of the airways such as 
asthma and chronic obstructive pulmonary disease. First, adenosine 
administered by inhalation was shown to be a powerful bronchoconstrictor of 
asthmatic but, importantly, not of normal airways (Cushley et al., 1983). 
Second, increased formation of adenosine occurs in chronically inflamed 
airways as demonstrated by elevated levels of adenosine both in BAL fluid 
and exhaled breath condensate of asthmatic patients with elevations 
correlating with the degree of inflammatory insult (Driver et al., 1993; Huszar 
et al., 2002). Third, blockade of adenosine re-uptake by dipyridamole 
increased the bronchoconstrictor response to adenosine in asthma indicating 
that accumulation of extracellular adenosine was closely associated with the 
asthmatic airway response (Cushley et al., 1985). Finally, a recent study has 
established that the administration of adenosine 5’-monophosphate provoked 
airflow limitation in dogs with cadmium chloride-induced airway inflammation 
but not on healthy individuals (Hirt et al., 2007).  
This has led to the current hypothesis that release of histamine and other 
spasmogens from resident airway mast cells may account for the 
bronchoconstrictor response to inhaled adenosine in asthma. Mast cells have 
been traditionally associated with allergic reactions through IgE engagement 
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on the high affinity FceRI receptors, leading to degranulation of cytoplasmic 
granules and release of biologically potent mediators (i.e. histamine). In 
addition, adenosine (as well as bacterial and viral antigens, cytokines and 
neuropeptides among others) can provoke the secretion of inflammatory 
mediators from these cells, in a selective process that is independent of 
degranulation. Recently, mast cells have been reported to mediate 
adenosine-induced airway hyperresponsiveness in a degranulation-
independent fashion (Hua et al., 2008). Both adenosine mediated mast cell 
degranulation and differential secretion of inflammatory mediators 
(degranulation-independent) have raised great interest and are being widely 
explored.  
 
Aim of this work 
Numerous experiments conducted on experimental animal models sustain the 
potential of selective AR activation in the treatment of inflammation and 
inflammation-related diseases, but this potential has failed to translate into 
novel therapies. For this reason, the further development of AR-based 
strategies of immunomodulation requires knowing the exact molecular 
mechanisms that mediate inhibition/stimulation of inflammatory processes by 
adenosine. The aim of this work is to identify and characterize cellular signals 
triggered by activation of specific ARs implicated in pro and anti-inflammatory 
signaling employing a pharmacogenomics approach.    
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Material and Methods 
Cell culture 
The human mast cell line-1 (HMC-1) was a kind gift from Dr. J. H. Butterfield, 
Mayo Clinic, Rochester, MN, USA. These cells were cultured at 37 °C in 
saturated humid atmosphere under 5 % CO2 in Iscove's Modified Dulbecco's 
Medium (IMDM, Invitrogen) supplemented with 10 % fetal bovine serum with 
iron (Invitrogen), 1.2 mM Alphathiglycerol (Sigma) and 100’000 units/l 
Penicillin and 100mg/l Streptomycin (complete IMDM). Subculturing was done 
when the cells reached a concentration of 106 cells/ml (every third day). They 
were split in a ratio of 1:2. 
Cell stocks were obtained by centrifuging the cultured cells (10 minutes, 1200 
rpm) and resuspending them with freezing media (complete media as 
described above with 5% DMSO) to reach a density of around 5 Mio cells/ml. 
Aliquots were slowly frozen until they reached -80°C and then transferred to 
liquid nitrogen. To start a new culture, the aliquots were thawed to 37°C, 
transferred into falcon tubes (Greiner), diluted with pre-warmed complete 
medium and collected by centrifugation (10 minutes, 1200 rpm). Cells were 
then resuspended with pre-warmed complete medium and transferred into 
T75 flasks (75cm2, Nunc A/S).  
 
Cell treatments 
All chemicals were obtained from Sigma-Aldrich (Switzerland) unless 
otherwise indicated. HMC-1 cells were seeded at 8 x 105 cells/ml and allowed 
to settle overnight. They were then treated with concentrations from 0.1µM to 
100µM of the following chemicals: the adenosine analogue NECA (5′-N-
Ethylcarboxamido-adenosine), the selective adenosine receptor A2A agonist 
CGS-21680 (9-Chloro-2-(2-furanyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine) 
and the selective adenosine receptor A2A antagonist SCH-58261 (7-(2-
phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-
c]pyrimidine) or a combination of NECA and SCH-58261. The length of 
treatment varied between 30 minutes and 72 hours (specific treatment 
schemes are indicated together with the results). Cells were pretreated with 1 
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U/ml adenosine deaminase (Roche) to remove any pre-existing endogenous 
adenosine for 20 minutes.  
 
Cell viability assay 
HMC-1 cells were seeded in a 96-wp and allowed to recover overnight before 
exposing them to increasing amounts of NECA, CGS-21680 and SCH-58261 
for 24 hours. The metabolic activity was quantified after different treatment 
times using the redox indicator dye Alamar Blue (Invitrogen). After incubation, 
the fluorescent signal was measured by the Luminescence Spectrometer 
LS55 (PerkinElmer) with an excitation wavelength of 560nm and an emission 
wavelength of 590nm. The recorded values were corrected for unspecific 
fluorescence (background) and the decrease in cell viability was calculated in 
reference to the untreated control (100%). 
 
Genome wide gene expression analysis 
Global gene expression analysis was done in 4 independent experiments, 
consisting of the treatment with 10 µM NECA and 10 µM CGS-21680, and 
untreated cells as a baseline control. 
After 3h treatment of HMC-1 cells total RNA was extracted as described in the 
following section. The quality of RNA was determined on the Agilent Lab-on-
a-chip Bioanalyzer 2000 (Palo Alto, CA, USA). Samples with a total area 
under 28S and 18S bands of less than 65% of total RNA, as well as a 
28S/18S ratio of less than 1.5, were considered to be degraded and therefore 
excluded from microarray analysis. cDNA was then synthesized as described 
in the following section, and complementary RNA (cRNA) labeled with the IVT 
labeling kit (Affymetrix). cRNA quality was assessed with the Agilent Lab-on-
a-chip Bioanalyzer 2000. The biotin-labeled cRNA was fragmented and 
hybridized on Human Genome U122 plus 2.0 microarrays (Affymetrix) 
following the manufacturer’s instructions. After hybridization periods of 16 
hours the microarrays were automatically washed and stained on the 
Affymetrix Fluidics Station 450. Staining of the hybridized probes was 
performed with fluorescent streptavidin-phycoerythrin conjugates (1 mg/ml; 
Molecular Probes). The subsequent scanning of DNA microarrays was carried 
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out on an Affymetrix scanner 3000 7G. The generated data was then 
normalized and analyzed using the GeneSpring 7.3.1 sofware (Agilent, Palo 
Alto, CA, USA). We employed pair-wise analysis based on B - Fabric 
infrastructure tool (Functional Genomics Center, ETH/University of Zurich, 
Switzerland) and the GeneGo Metacore (www.genego.com) integrated 
software for data mining and functional analysis of experimental data. The 
gene ontology database (www.geneontology.org) was also consulted for the 
molecular function of each transcript.  
 
Real time polymerase chain reaction (RT-PCR) 
Cells were collected by centrifugation at the corresponding time points and 
total RNA was recovered using the Qiashredder and Rneasy mini kit 
(Qiagen). Concentration and quality of total RNA were measured with the 
Ultraspec 2100 pro spectrophotometer (Amersham Biosciences). Samples 
with a UV absorbance 260/280 ratio of 1.8 to 2.1 were considered to be 
suitable for cDNA synthesis. The RNA samples were stored at -20°C until 
use. Complementary DNA (cDNA) was synthesized using the one-cycle cDNA 
synthesis kit followed by a sample cleanup to optimize volumes and 
concentration of the cDNA (GeneChip sample cleanup module, Affymetrix). 
Specific primers for the selected transcripts as well as TaqMan probes were 
obtained from Applied Biosystems. 40 ng of cDNA were mixed with 90nM of 
forward and reverse primers and supplemented with 25nM of the 
corresponding TaqMan probe in a final volume of 20 µl. The reactions were 
performed in a 7500 Fast Real-time PCR-System ABI 7500 (Applied 
Biosystems) in 40 cycles (95 °C for 3 sec, 60 °C for 30 sec) after an initial 20 
sec incubation at 95 °C, and was analyzed with the 7500 Fast System SDS 
Software System (Applied Biosystems). The fold change in expression of 
each gene was calculated with the 2-Delta Delta C(T) method (Livak and 
Schmittgen, 2001). Briefly, this method compares Ct values of the samples to 
Ct values of the untreated controls. For a given well, the threshold cycle (Ct) 
represents the PCR cycle at which the software first detects a noticeable 
increase in reporter fluorescence above a baseline signal. Each of these 
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values had been normalized to an appropriate endogenous housekeeping 
gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
 
Western blot 
Preparation of whole cell lysates  
HMC-1 at a concentration of 106 cells/ml were harvested after treatment to the 
indicated concentrations of the corresponding chemicals for varying 
incubation times, collected by centrifugation, washed with 1x PBS and lysed 
with 180µl 1x lysis buffer (50mM Tris, 150mM NaCl, 1% Nonidet P40, 0.5% 
sodium deoxycholate and a protease inhibitor cocktail tablet (Roche, 
Switzerland) per 25 to 50 ml buffer). After lysis, the samples were sonicated 
(5 cycles, 10 seconds, 70% power; Banderlin Sonopuls) and centrifuged to 
remove the insoluble fraction.  
Supernatants were aliquoted and stored at -20°C until use.  
 
Protein quantification 
Protein concentration was determined by the Bradford method. Briefly, 2ul of 
lysate was incubated with 1 ml of 1x Bio-RAD Protein Assay (Bio-Rad 
Laboratories) for 5 minutes in the dark. Absorbance at 595 nm was then 
determined on an Ultraspec Plus spectrophotometer (Amersham Pharmacia 
Biotech, Little Chalfont, Buckinghamshire, UK). Three BSA standards (0.2, 
0.5, 0.9 ug/ml) were employed to construct a calibration curve against which 
the protein concentration of the samples was calculated by extrapolation. 
 
SDS-Page and Western Blot analysis 
30µg of protein in 1x Laemmli buffer were separated on a 10% 
polyacrylamide gel by standard SDS-PAGE technique (Laemmli, 1970), using 
a Bio-Rad vertical electrophoresis unit. Electrophoresis was accomplished at 
35 mA per gel for 1 hour in 25mM Tris, 125mM Glycin, pH 8.6, containing 
0.1% SDS. A protein size marker ladder to show different known sizes of 
proteins was used with every SDS gel (Precision Plus Protein All Blue 
Standards, Biorad). After electrophoresis, proteins were transferred onto 
Immune-Blot polyvinylidene difluoride (PVDF) membranes (0.2 µgm pore 
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size, Bio-Rad) using the Bio-Rad tank transfer system. The PVDF membranes 
were soaked in methanol and equilibrated in transfer buffer (25mM TRIS, 125 
mM Glycine, pH 8.6, containing 0.025% SDS). The transfer was carried out at 
60V for 1 hour at 4°C.  
After transfer, the membranes were incubated for 16 hours at 4°C with 
blocking solution (5% non-fat dry milk, 3% BSA in TBST (10mM Tris, 150 mM 
NaCl, 0.05% Tween 20, pH 7.4) to block any unspecific binding sites. NR4A2 
antibody (Santa Cruz Biotechnology) was employed as primary antibody at a 
dilution of 1:2000 with 2.5% BSA in TBST. Incubation was carried out in glass 
tanks for 1 hour at room temperature on an orbital shaker. In a similar fashion, 
GAPDH (Ambion, USA) antibody diluted 1:10’000 with 2.5% BSA in TBST 
was employed for 30 min as an internal normalization control. Following the 
incubation with the primary antibody the membranes were washed 3 times for 
10 minutes in 3% non-fat dry milk in TBST and then incubated for 1 hour with 
the appropriate peroxidase conjugated secondary antibodies (anti-rabbit IgG 
for NRA2; anti-mouse IgG for GAPDH, both diluted 1:80’000) in 3% non-fat 
dry milk in TBST. Then, the membranes were washed in 3% non-fat dry milk 
in TBST followed by TBST and TBS (3x 10 min). Finally, enhanced 
chemiluminescence was performed with SuperSignal West Femto Maximum 
(Pierce/ Socochim, 5 minutes) and images were acquired on a LAS-3000 
(Fujifilm Life Science, Japan). The intensity of the NR4A2 signals was 
normalized against the GAPDH content in each sample.  
 
Luciferase reporter gene assay 
The 4xNBRE-Luc reporter plasmid was a kind gift from H. Harant. This vector 
carries the firefly luciferase gene under control of the NBRE (NGFI-B 
responsive element) sequence (AAGGTCA). 1.5 x 106 HMC-1 cells in 1ml 
were seeded into a 6 well plate and were co-transfected with the 4xNBRE-Luc 
reporter and the pRL-TK vector (Promega), which constitutively expresses the 
renilla luciferase gene. The ratio of co-transfection 4xNBRE-Luc: pRL-TK was 
30:1 and Lipofectamine 2000 (Invitrogen) was employed as transfction ragent. 
4 hours post transfection, the medium was changed and the cells were 
allowed to recover for 24 hours before exposure to the indicated 
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concentrations of the selected chemicals. Following exposure, cells were 
collected by centrifugation at varying times, washed once with 1x PBS and 
lysed with 250 µl of lysis buffer (Promega). Lysis was completed by agitating 
for 20 minutes on an orbital shaker followed by centrifugation for 1 minute at 
13’200 rpm to remove the insoluble fraction. 30 µl of the supernatant were 
used to determine the expression of firefly and renilla luciferase using the 
Dual Luciferase system (Promega), as indicated by the manufacturer. Briefly, 
firefly luciferase activity was first measured by adding Luciferase Assay 
Reagent II (Promega). After quantification, this reaction is quenched and the 
renilla luciferase reaction is initiated by adding Stop&Glo Reagent (Promega), 
which generates a second luminescent signal. Induction of the reporter gene 
was then calculated from the ratio of activity of the two enzymes. All 
luminescent measurements were performed automatically in a 96 well-plate in 
a Luminescence Spectrometer (MLX, Dynex).  
 
MIP-1-β  assay  
A human MIP-1-β Elisa kit (RayBiotech) was used to determine the level of 
MIP-1-β protein in the supernatant of HMC-1 cells. HMC-1 cells were seeded 
at a concentration of 2 x 106 cells in 1ml in a 24 well plate. 16 hours later the 
cells were treated with the indicated concentrations of NECA and CGS-21680 
for varying lengths of time. The MIP-1-β assay was performed following the 
manufacturer’s instructions. The plate was read at 450 nm on Mulitskan RC 
(Thermo Labsystems). 
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Results 
 
Expression of ARs in HMC-1 cells 
HMC-1 cells exhibit a phenotype that is in several aspects similar to tissue 
resident mast cells. Therefore, we selected this cell line for the evaluation of 
genome-wide transcriptional reprogramming upon AR activation this cell line. 
Previous reports showed that HMC-1 cells show expression of functional A2A, 
A2B and A3 ARs (Feoktistov et al., 2003). In order to rule out the possibility 
that mutagenic events resulting from perpetuation of this cell line had affected 
AR expression, we decided to confirm the expression of these receptors in the 
cells in culture in our lab. Figure 3 shows the relative abundance of AR 
subtypes as determined by RT-PCR. In agreement with previous reports, we 
observed that A2B and A3 are the predominant AR subtypes, while A2AAR 
represent less than 5% of ARs expressed in resting HMC-1. As expected, 
transcripts for A1AR couldn’t be detected.  
Figure 3. RT-PCR analysis of mRNA encoding AR subtypes was performed 
as described. Values are expressed as percentage GAPDH (house keeping 
control) and represent the mean of three independent measurements ± SEM.  
 
 
Toxicity of AR ligands on HMC-1 cells  
Next, we wanted to determine the toxicity threshold of the compounds 
selected for the pharmacological stimulation of the ARs (NECA, CGS-21680 
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and SCH-58261). Figure 4 shows the viability of HMC-1 cells with increasing 
doses of these compounds. While concentrations of NECA of 100µM did not 
affect cell viability, the same concentration of CGS-21680 reduced it to 75% 
whereas 100µM of SCH-58261 provoked an even more drastic effect (viability 
below 10%). On the other hand concentrations of 10µM or lower of each of 
the three chemicals did not show a toxic effect. The inclusion of 0.5% DMSO 
in cell culture medium did not affect viability (vehicle control), while 5% of this 
solvent caused almost a 100% reduction in cell viability.     
 
 
Figure 4. Viability of HMC-1 cells upon incubation with increasing 
concentrations of the indicated compounds for 24 hours, expressed as 
percentage relative to untreated cells.  
 
 
 
Transcriptomics analysis of selective AR activation in HMC-1 
cells 
In order to identify signals indicative of pro- or anti-inflammatory signaling, 
selective pharmacological activation of AR subtypes followed by genome-wide 
profiling was employed. For the analysis of general adenosine signaling, the 
analogue NECA was selected, while CGS-21680 was preferred for the 
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identification A2A-specific transcripts. After 3h exposure the cells were 
collected and processed for the determination of expression profiles that 
cover sequences of 47’000 human transcripts. The hybridization results were 
normalized and subsequently filtered using a significance value of P<0.05. 
The overall analysis revealed a strong transcriptional response to NECA, with 
a set of transcripts common to CGS-21680. Table 1 summarizes the fold 
changes of the highest upregulated transcripts induced after treatment of 
HMC-1 cells with NECA or CGS-21680, as compared to untreated controls.  
The number of transcripts affected by CGS-21680 as well as the intensity of 
these changes was more moderate than those by NECA. 
 
 
Gene 
Name Description 
NECA 
FC 
CGS 
FC 
NR4A2* Nuclear receptor subfamily 4, group A, member 2 33.52 15.2 
STC1* Stanniocalcin 1 25.37 4.77 
NR4A3* Nuclear receptor subfamily 4, group A, member 3 24.13 13.87 
CREM* CAMP responsive element modulator 13.57 10.04 
EGR3 Early growth response 3 10.16 5.44 
RGC32 response gene to complement 32 9.54 3.99 
HOMER1 Homer homolog 1 (Drosophila) 7.95 4.09 
FOSB FBJ murine osteosarcoma viral oncogene homolog B 6.91 4.05 
CGA Glycoprotein hormones, alpha polypeptide 6.14 2.20 
ELL2* Elongation factor, RNA polymerase II, 2 6.14 3.72 
JMY Junction-mediating and regulatory protein 5.96 2.71 
ZEB1 Transcription factor 8 (represses interleukin 2 expression) 5.42 2.75 
EGR1 Early growth response 1 5.07 5.63 
BCL2L11* BCL2-like 11 (apoptosis facilitator) 4.99 3.14 
ITK IL2-inducible T-cell kinase 4.76 3.5 
PLAUR* Plasminogen activator, urokinase receptor 4.58 3.4 
TP53INP2 p53 induced nuclear protein 2 3.88 2.42 
IL2RB Interleukin 2 receptor, beta 3.78 2.52 
EGR2 Early growth response 2 (Krox-20 homolog, Drosophila) 3.72 3.5 
 
Table 1. Top regulated transcripts by NECA and CGS-21680 treatment 
(P<0.05). NECA FC = Fold changes upon treatment with 10µM of NECA. 
CGS FC = Fold changes upon treatment with 10µM of CGS-21680. Asterisks 
indicate transcripts for which two or more set of probes were upregulated. 
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An additional group of transcripts became exclusively upregulated upon 
NECA treatment, including MIP-1β (also known chemokine CCL4; 4.4 fold), 
CXCR4 (chemokine CXC4 receptor; 3.9 fold), VEGF (vascular endothelial 
growth factor, 3.35 fold), PLA2G6 (Phospholipase A2, group VI; 3.01 fold) and 
CASP9 (caspase 9; 3.13x). Among the NECA-specific downregulated 
transcripts we found IL-7 (-3.6 fold) and UBTF (upstream binding transcription 
factor RNAS polI; -3.54 fold).  
Even though this high dose of CGS-21680 (10µM) is likely to activate not only 
the A2A but also A3 receptors on HMC-1, a small group of transcripts appear 
to be exclusively up- and down-regulated by this treatment, including the 
NAB2 (NGFI-A binding protein, also known as EGR1 binding protein 1; 2.1 
fold), RXRβ (retinoid X receptor beta; -2 fold) and IKBKB (inhibitor of Kappa 
light polypeptide enhancer in B-cells; 2.05 fold). These transcripts represent 
interesting potential targets for the modulation of inflammatory/immune 
responses by adenosine (i.e. the EGR1/NAB2 in the regulation of granulocyte 
and monocyte lineage commitment and maturation). 
 
 
Characterization of selected downstream targets  
Based on the results of our pharmacogenomics screening, we selected three 
genes for further study: MIP-1β, which appeared to be exclusively upregulated 
by NECA and the nuclear orphan receptors NR4A2 and NR4A3. 
 
MIP-1β  upregulation 
In order to further characterize the induction of MIP-1β we examined the 
induction of this transcript by real-time PCR. Figure 5 shows the rapid 
upregulation of MIP-1β after treatment with 10µM NECA, which peaks by 3h 
and is followed by a decrease to baseline levels within 24h. CGS-21680, in 
contrast, failed to induce this inflammatory gene product, suggesting that the 
A2AAR does not contribute to the induction of this protein.  
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Figure 5. Time dependent induction of MIP-1β transcript. HMC-1 cells were 
treated for the indicated times with 10µM of each AR ligand and analyzed by 
RT-PCR as described. Fold changes are calculated in relation to untreated 
controls. Values represent the mean of three experiments ± SEM.  
 
Activation of human cultured mast cells by CD40 ligand was recently shown to 
stimulate the release of MIP-1β and other cytokines in absence of 
degranulation (Fischer et al., 2006). Therefore, we wanted to determine 
whether AR activation could also lead to MIP-1β protein release in HMC-1 
cells. For this reason, changes in MIP-1β concentration in cell culture medium 
were assessed by ELISA 3h after AR activation alone or in combination with  
LPS. Fig 6 shows that 10µM NECA results in a strong release of MIP-1β from 
HMC-1 cells, in agreement with the induction of transcription of this gene 
product (Fig 5). CGS-21680 caused a pronounced but somewhat milder 
release of MIP-1β. Interestingly, CGS-21680-mediated MIP-1β release does 
not match the abundance level of its transcript since A2AAR activation does 
not upregulate MIP-1β transcription (Fig 5). This may imply that transcriptional 
induction and release of pre-formed MIP-1β are two independent events, and 
that activation of A2AAR can selectively modulate the release of this 
chemokine without inducing its transcription. Alternatively, the increment of 
β  1 
 26 
MIP-1β in the cell culture medium by CGS-21680 may reflect the activation of 
ARs other than A2A at this relatively high dose.  
Interestingly, the concomitant treatment of HMC-1 cells with NECA and LPS 
reveals a synergism between these two pathways. While LPS alone did not 
induce MIP-1β secretion, treatment of HMC-1 cells with LPS and NECA 
provoked an exaggerated release of this chemokine in the cell culture 
medium. Additional experiments would be required to determine whether this 
synergism takes place at the signal transduction level downstream of ARs and 
toll-like receptor 4 (TLR4, the receptor activated by LPS) or at other levels.  
 
Figure 6. MIP-1β concentration in cell culture medium. HMC-1 cells were 
treated for 3h as indicated and cell culture medium analyzed by ELISA. 
Values represent the mean of three independent measurements ± SEM.  
 
 
Nuclear orphan receptors 4A  
This subfamily of nuclear orphan receptors is constituted by 3 members: 
NR4A1 (also known as Nur77 or nerve growth factor inducible B – NGFI-B), 
NR4A2 (also known as Nurr1) and NR4A3 (also known as NOR1). Two 
members of this subfamily are among the AR-induced top-regulated 
transcripts, with their induction being higher after NECA than upon CGS-
21680 treatment. 
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RT-PCR 
Figures 7A and 7B show the induction of NR4A2 and NR4A3 within 6 hours of 
treatment with 1µM CGS-21680, 10µM NECA or the combination 10µM NECA 
plus 10µM SCH-28261. NECA upregulated NR4A2 and NR4A3 to levels 
comparable to the detected by the transcriptomics analysis, with maximal 
induction of 240 fold and 98 fold respectively, 1h after treatment. In contrast, 
1µM CGS-21680 (a dose that allows specific A2A activation) failed to induce 
them. Remarkably, the combined treatment of NECA and SCH-28261, results  
Figure 7. Time dependent induction of NR4A2 (A), NR4A3 (B), NR4A1 (C) 
and CREM (D). HMC-1 cells were treated with AR ligands for the indicated 
times and analyzed by RT-PCR as described. Fold changes are calculated 
taking untreated samples as baseline. Values represent the mean of three 
measurements ± SEM. 
A B 
C D 
 28 
in further upregulation of these nuclear orphan receptors, with fold changes 
up to 429 and 376 over the untreated controls respectively, implying that the 
induction of these two transcription factors rely on the activation of ARs other 
than A2A.  
This interplay between global and A2AAR activation is, nevertheless, not 
conserved to the third member of this family of receptors, the NR4A1: 
simultaneous treatment with NECA and SCH-28261 does not significantly 
increase NR4A1’s marginal upregulation by NECA (4.2-fold, Fig 7C). In a 
similar fashion, induction of the cAMP-response element modulator (CREM, a 
top-regulated gene from the transcriptomics screening) reaches 55-fold 
change when treated with NECA (Fig 7 D). Treatment with CGS-21680 or the 
combination of NECA and SCH-58261 induces CREM only marginally, 
indicating that simultaneous activation of all ARs is required to achieve 
maximal CREM induction. 
 
NR4A2 protein levels 
In the light of these findings, we wanted to determine whether the observed 
upregulation of NR4A2 and 3 transcripts correlate with changes in protein 
abundance. Figure 8A shows a western blot analysis of NR4A2 upon 
treatment with either CGS-21680 or the combination of NECA and SCH-
58261. NR4A2 levels increase after NECA and NECA plus SCH-58261 as 
early as 12h after treatment, returning to normal levels at around 72 h (not 
shown). However, treatment with CGS-21680 (10µM)  results in a much 
weaker upregulation of NR4A2 protein.  
To further characterize these changes at earlier time-points, cells were 
exposed either to NECA or CGS-21680 (1µM) for 3 and 6h (Fig 8B). 
Interestingly, NECA upregulated NR4A2 protein as early as 3h while selective 
A2A activation by CGS-21680 caused only a marginal increase in NR4A2.  
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Fig 8. Western blot analysis of NR4A2 protein. HMC-1 cells were treated with 
10µM  NECA (N), 10µM  CGS-21680 (C) or the combination of 10µM  
NECA and 10µM   SCH-58261 (N+S) for the indicated time points . UT= 
untreated. GAPDH is included as a loading control. 
 
 
Transcriptional activity of NR4A receptors 
NR4A orphan receptors bind to well-defined DNA sequences located in 
promoter regions of various genes and activate their transcription. The nerve-
growth factor responsive element (NBRE) is a well-characterized NR4A 
consensus sequence. Here, we employed an NBRE-luciferase reporter 
plasmid (Fig 9A) to assess the transcriptional activity of AR-induced NR4A 
receptors. Figure 9B shows the time-dependent induction of luciferase activity 
upon treatment with NECA, CGS-21680 or NECA together with SCH-58261. 
NECA and NECA plus SCH-58261 induced a robust response, which peaked 
at 24h with 40-fold reporter induction compared to untreated controls and 
returned to background values at 72h. CGS-21680, in contrast, did not induce 
luciferase expression significantly. 
 
 
 
N CGS 
UT   3h     6h   
GAPDH 
NR4A2 
UT   3h     6h   
 
 
 
UT    N     C   N+S   N     C   N+S   N    C    N+S 
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Figure 9. A) Vector maps of the reporter plasmids. In 4xNBRE-LUC the 
expression of the firefly luciferase gene is under the control of 4 NBRE 
repeats. The plasmid Lt-K encodes the renilla luciferase gene, which is 
consitutively expressed, and was co-transfected with the 4xNBRE-LUC as a 
transfection control. B) Induction of NR4A-mediated transcriptional activity by 
AR activation. HMC-1 cells were transfected with the indicated plasmids and 
treated with 10µM NECA, 10µM CGS-21680 and 10µM NECA together with 
10µM SCH-58261. Whole cell lysates were obtained at the indicated times 
and assessed for luciferase activity. 
 
 
Interplay between ARs and PMA/Ionomycin in NR4A2 and 
NR4A3 signaling 
NR4A receptors are immediate responsive genes that can be induced by a 
variety of stimuli. Recent evidence indicates that NR4A2 induction represents 
a point of convergence of different cytokine signaling pathways, indicating a 
common role for this transcription factor in mediating multiple inflammatory 
signals (Mcevoy et al., 2002). Therefore, we wanted to assess whether the 
stimulation of ARs could alter the effect of other inflammatory stimuli on NR4A 
A 
 
B 
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upregulation and activation. Phorbol 12-myristate 13-acetate (PMA) is a 
diester of phorbol that is usually employed together with the calcium 
ionophore Ionomycin (I) for the study of cytokine induction during the 
inflammatory response in mast cells (and other cell types). Stimulation of 
HMC-1 cells with the combination of PMA/I for 2h resulted in a very strong 
induction of NR4A2 and NR4A3 and a concomitant 104-fold increase in their 
transcriptional activity compared to untreated controls with the NBRE-LUC 
reporter. In the presence of 10µM NECA, the induction of these orphan 
receptors was markedly accentuated (more than 1000-fold over baseline 
controls), with activity levels more than 3-times higher than with PMA/I alone 
(Fig. 10B). In contrast, the addition of 10µM CGS-21680 to the PMA/I mixture 
significantly reduced NR4A2 and NR4A3 induction by more than 50% and the 
NBRE transcriptional activity by around 30%. 
 
 
 
  
 
 
 
 
 
 
Figure 10. A) Induction of NR4A2 and NR4A3 transcripts by PMA/I alone or in 
combination with NECA (PMA/I + NECA) or CGS-21680 (PMA/I + CGS). B) 
Induction of NR4A-mediated transcriptional activity by PMA/I and AR 
agonists. Values represent the mean of three measurements ± SEM. 
Asterisks indicate significant differences (P < 0.05) when compared to PMA/I 
treatment.   
 
 
A 
* 
* 
B 
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Discussion 
 
There is overwhelming evidence indicating that mast cell mediators, such as 
cytokines and histamine have a key role in airway inflammation and 
hyperresponsiveness, and that chronic mast cell activation contributes to the 
pathophysiology of diverse diseases. In addition, mast cells have been 
reported to mediate adenosine effects in airways (Hua et al., 2008).  
In this study we employed a pharmacogenomics approach for the 
identification of adenosine receptor subtype-specific cellular signals in human 
mast cells. As a result of this screening, we have detected a link between AR 
activation and MIP-1β chemokine secretion in human mast cells. In addition, 
we have identified the role of AR subtypes in regulating the induction and 
function of NR4A2 and NR4A3 in the context of inflammatory signaling.  
 
MIP-1-β  induction/secretion by NECA in HMC-1 cells  
MIP-1β together with other MIP-1 family members plays a central role in acute 
and chronic inflammation by virtue of their potent modulator of cytokine 
production and lymphocyte chemoattractant actions. Our genome wide mRNA 
screening revealed a 4.4-fold upregulation of MIP-1β over basal levels 3h 
after NECA treatment that was confirmed by real time PCR. Furthermore, 
treatment with this synthetic adenosine analogue induced a robust MIP-1β 
release by HMC-1 cells, reaching 834pg/ml of cell culture medium - over 60 
times more than basal levels (13pg/ml). To the best of our knowledge, this is 
the first study establishing a link between AR activation and MIP-1β release in 
mast cells. Research on this cell type has been mainly focused in 
degranulation-related events in allergy and asthma. Nevertheless, it is 
becoming more evident that mast cells contribute to the development of many 
pathological conditions, including autoimmune disease (Benoist and Mathis, 
2002), inflammatory arthritis (Lee et al., 2002) and tumorigenesis (Coussens 
and Werb, 2001) and they are now being acknowledged as versatile effector 
cells in innate and acquired immunity – beyond their well-characterized IgE 
mediated effects.  
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Our findings suggest that adenosine can contribute to the perpetuation of 
inflammation by directing the recruitment of inflammatory cells by mast cells. 
The ELISA analysis also revealed that activation of A2AAR with CGS-21680 
induced MIP-1β secretion, up to 515 pg/ml (61% of that by NECA). This 
finding contests other studies showing that A2AAR activation can limit MIP-
1β  secretion during inflammation. For example, in LPS-stimulated human 
neutrophils, the engagement of the A2AAR selectively prevented the 
expression and release of MIP-1β, TNF-α, MIP-1α, MIP-2α, and MIP-
3α (Mccoll et al., 2006). Similarly, activation of A2AAR suppresses 
macrophage function and reduces the degree of kidney injury during 
glomerulonephritis via suppression of the glomerular expression of MIP-1β 
among other chemokines (Garcia et al., 2008). One possible explanation for 
this discrepancy could be that the relatively high concentration of CGS-21680 
employed in this study (10µM) binds not only to the A2AAR (Ki= 27nM) but 
also the A3AR (Ki= 67nM), which is highly expressed in HMC-1 cells and has 
been associated with proinflammatory events. Therefore, it is possible that the 
MIP-1β induction observed upon CGS-21680 treatment reflects a combined 
effect on A2A and A3ARs. Complementary experiments with lower doses of 
CGS-21680 (which exclusively activates the A2AAR) and A3AR selective 
agonists would be required to confirm this hypothesis.  
In the context of HIV infection, MIP-1β has been identified as a soluble 
suppressive factor (HIV-SF) released by immortalized and primary CD8+ T 
cells (Cocchi et al., 1995). CCR5 is the natural receptor for MIP-1β, MIP-1α 
and RANTES, and participates in the interaction between HIV-1 and CD 8+ T-
cells, an early step in viral uptake and replication. As a consequence of this 
shared receptor usage, the entrance of HIV-1 (in CCR5-dependent strains) 
can be blocked by the CCR5 ligands, including MIP-1β. Hydroxyurea and 
rapamycin are examples of drugs that increase the concentrations of MIP-1β, 
MIP-1α and RANTES, and it is considered as a suitable approach to inhibit 
HIV-1 (Heredia et al., 2003). Based on our findings, activation of ARs (alone 
or in combination with other drugs) may represent a novel strategy to increase 
MIP-1β release by mast cells, that could potentially affect HIV-1 uptake by CD 
8+ T-cells. 
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Induction of functional nuclear orphan receptors by selective 
AR activation 
NR4A orphan receptors are transcription factors belonging to the superfamily 
of steroid nuclear hormone receptors that have been associated with different 
cellular processes such as apoptosis in lymphocytes (Winoto and Littman, 
2002), development of dopaminergic neurons (Zetterstrom et al., 1997) and 
glucose metabolism (Pei et al., 2006). It has been reported that this family of 
orphan receptors represent NF-κB and LPS-inducible genes in macrophages 
(Pei et al., 2005) and that NR4A1 expression leads to induction of 
inflammatory genes, potentiating NF-κB pro-inflammatory signaling by IKKi 
kinase upregulation (Pei et al., 2006). In addition, NR4A2 has been 
recognized as an important inducible factor in inflamed synovium and as a 
target of adenosine-mediated anti-inflammatory effects of methotrexate 
(Ralph et al., 2005).  
The results presented here establish, for the first time, a direct link between 
AR engagement and activation of two members of the NR4A subfamily of 
nuclear receptors, namely NR4A2 and NR4A3. Furthermore, we uncover 
divergent effects between the AR subtypes on the induction of these orphan 
receptors. First, we demonstrate that AR activation leads to a sharp increase 
in NR4A2 and NR4A3 mRNA and protein levels (but not of NR4A1) and that 
this upregulation is multiplied by blocking the A2AAR. Second, we present 
evidence indicating that the induction of these orphan receptors is 
accompanied by an increase in their transcriptional activity. Third, we 
establish that activation of A2AAR not only counterbalances general adenosine 
effects, but the engagement of this AR can also modulate the induction of 
NR4A2 by other inflammatory stimuli.   
This remarkably high induction of NR4A2 and NR4A3 peaks between 1 and 2 
hours after AR stimulation and is accompanied by an increase in their 
transcriptional activity that returns to background level after 48h, suggesting 
important transcriptional downstream effects. In contrast to other members of 
the nuclear hormone receptor superfamily, the crystal structure and NMR data 
indicate that the ligand-binding pocket of NR4A receptors is covered by 
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hydrophobic residues. These receptors have been demonstrated to function 
as ligand-independent constitutively active transcription factors whose activity 
is controlled at the level of protein expression and post-translational 
modifications (Codina et al., 2004; Fahrner et al., 1990). For this reason, 
adenosine’s effects on the abundance of these transcription factors could 
have broad biological implications. On one hand, the activation of pro-
inflammatory ARs (i.e. A2B and A3ARs) in activated inflammatory cells could 
act as an amplification signal resulting in very high levels of NR4A 
transcriptional activity and expression of a larger set of NBRE-responsive 
genes. On the other hand, A2AAR activation could directly downregulate 
NR4A2 and NR4A3-dependent inflammatory genes.  
NR4As also influence the function of other inflammation-associated 
transcription factors. For example, NR4A1 and 2 form heterodimers with 
retinoic acid receptor and may influence retinoid signaling (Wallen-Mackenzie 
et al., 2003). AR activation can therefore affect the number of NR4A-
containing complexes. A2B and A3AR-mediated accumulation of NR4A2 and 
NR4A3 would translate in a higher proportion of transcriptional complexes 
containing these orphan receptors. Conversely, A2AAR activation would limit 
the availability of NR4A2 and NR4A3 for heterodimerization with other TFs. 
As a result of this interplay, adenosine could affect the nature of these 
transcriptional complexes and, by extention, the range of transcribed genes. 
NR4A receptors can also crosstalk with other TFs and influence their activity, 
without necessarily interacting with them. A recent study has established that 
NR4A receptors and the estrogen-related receptors NR3B mutually repress 
each others transcriptional activity (Lammi et al., 2007). Similarly, NR4A1 has 
been shown to negatively cross-talk with NF-κB (Harant and Lindley, 2004). 
Therefore adenosine can indirectly influence gene expression by other TFs by 
up or downregulating NR4A2 and 3.  
In view of the pleiotropic physiological roles of NR4As, adenosine’s effect on 
this group of transcription factors could have broad implications. A screen of 
all human gene promoters from a curated database of transcriptional start 
sites revealed 483 candidate genes containing one or two NBREs in their 
promoter regions (Zhao et al., 2008). Recently, NR4A orphan receptors have 
been proposed as downstream effectors of inflammatory signaling pathways 
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in macrophages (Pei et al., 2006). To the best of our knowledge, the role of 
this subfamily of orphan receptors has not been characterized in mast cells. 
The results presented here establish a novel signaling axis downstream of 
ARs involving the NR4A orphan receptor subfamily.  
Finally, we provide evidence showing that the nonselective AR activation 
strongly potentiated PMA/I-mediated induction of NR4As. In contrast, the 
concomitant treatment of HMC-1 cells with the A2AAR agonist CGS-21680  
partially reverted both NR4A2 and NR4A3 upregulation and their 
transcriptional activation induced by PMA/I, implying that the modulatory 
effects of A2AAR activation are not limited to adenosinergic proinflammatory 
signaling. These results suggest a previously undescribed mechanistic 
association between adenosine and other inflammatory signaling molecules 
(PMA/I), which may have profound implications for the development of new 
approaches for the control of inflammatory processes. 
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Conclusions and outlook 
 
The results presented in this thesis show that AR activation can have broad 
regulatory effects on human mast cells. First, we show that AR activation 
induces MIP-1β synthesis and release in HMC-1 cells. Activation of CD30 
ligand in mast cells has recently been shown to stimulate degranulation-
independent IL-8, MIP-1α and MIP-1β (Fischer et al., 2006), emphasizing the 
role of mast cells in regulating the inflammatory process. In turn, the secretion 
of chemokines by mast cells directs the recruitment of inflammatory cells, a 
pre-requisite for the development of chronic inflammatory diseases. In this 
context, our findings suggest that adenosine signaling can swiftly induce 
chemotaxis by MIP-1β release in mast cells.  
The second major finding of this study establishes a novel signaling axis 
downstream of ARs involving the NR4A orphan receptors in human mast 
cells. The remarkably high induction of NR4A2 and NR4A3 is accompanied by 
an increase in their activity, suggesting important secondary transcriptional 
downstream effects. Recent studies have revealed that nuclear receptors 
interact with other transcription factors and other cell signaling systems 
(reviewed by Glass and Ogawa, 2006). Therefore, it is likely that adenosine 
effects on NR4A orphan receptors will affect multiple signaling cascades, 
eliciting combinatorial secondary transcriptional responses. In this sense, 
further studies will be necessary to investigate effector molecules downstream 
of NR4A orphan receptors and possibly of other TFs. The work presented 
here establishes the use of pharmacogenomics as an efficient approach for 
the identification of early transcriptional signals upon selective AR activation. 
Likewise, a genome-wide screening could be of great value for the 
identification of secondary transcriptional waves at later time points.  
 
 
 
 38 
References 
 
 
Apasov, S., Chen, J.F., Smith, P. and Sitkovsky, M. (2000).  Blood 95(12): 
3859-67. 
 
Arch, J.R. and Newsholme, E.A. (1978).  Biochem J 174(3): 965-77. 
 
Basheer, R., Strecker, R.E., Thakkar, M.M. and McCarley, R.W. (2004).  Prog 
Neurobiol 73(6): 379-96. 
 
Benoist, C. and Mathis, D. (2002).  Nature 420(6917): 875-8. 
 
Blackburn, M.R. (2003).  Trends Pharmacol Sci 24(2): 66-70. 
 
Blum, D., Hourez, R., Galas, M.C., Popoli, P. and Schiffmann, S.N. (2003).  
Lancet Neurol 2(6): 366-74. 
 
Chan, E.S., Fernandez, P., Merchant, A.A., Montesinos, M.C., Trzaska, S., 
Desai, A., Tung, C.F., Khoa, D.N., Pillinger, M.H., Reiss, A.B., Tomic-
Canic, M., Chen, J.F., Schwarzschild, M.A. and Cronstein, B.N. (2006).  
Arthritis Rheum 54(8): 2632-42. 
 
Clancy, J.P., Ruiz, F.E. and Sorscher, E.J. (1999).  Am J Physiol 276(2 Pt 1): 
C361-9. 
 
Clark, A.N., Youkey, R., Liu, X., Jia, L., Blatt, R., Day, Y.-J., Sullivan, G.W., 
Linden, J. and Tucker, A.L. (2007).  Circ Res %R 
10.1161/CIRCRESAHA.107.150110 101(11): 1130-1138. 
 
Cocchi, F., DeVico, A.L., Garzino-Demo, A., Arya, S.K., Gallo, R.C. and 
Lusso, P. (1995).  Science 270(5243): 1811-5. 
 
Codina, A., Benoit, G., Gooch, J.T., Neuhaus, D., Perlmann, T. and Schwabe, 
J.W. (2004).  J Biol Chem 279(51): 53338-45. 
 
Coussens, L.M. and Werb, Z. (2001).  J Exp Med 193(6): F23-6. 
 
Cushley, M.J., Tattersfield, A.E. and Holgate, S.T. (1983).  Agents Actions 
Suppl 13: 109-13. 
 
Cushley, M.J., Tallant, N. and Holgate, S.T. (1985).  Eur J Respir Dis 67(3): 
185-92. 
 
Das, M. and Das, D.K. (2008).  IUBMB Life 60(4): 199-203. 
 
Day, Y.J., Marshall, M.A., Huang, L., McDuffie, M.J., Okusa, M.D. and Linden, 
J. (2004).  Am J Physiol Gastrointest Liver Physiol 286(2): G285-93. 
 
 39 
Dong, Q., Ginsberg, H.N. and Erlanger, B.F. (2001).  Diabetes Obes Metab 
3(5): 360-6. 
 
Donnelly, R. and Qu, X. (1998).  Clin Exp Pharmacol Physiol 25(2): 79-87. 
 
Donoso, M.V., Lopez, R., Miranda, R., Briones, R. and Huidobro-Toro, J.P. 
(2005).  Am J Physiol Heart Circ Physiol 288(5): H2439-49. 
 
Driver, A.G., Kukoly, C.A., Ali, S. and Mustafa, S.J. (1993).  Am Rev Respir 
Dis 148(1): 91-7. 
 
During, M.J. and Spencer, D.D. (1992).  Ann Neurol 32(5): 618-24. 
 
Edlund, A., Ohlsen, H. and Sollevi, A. (1994).  Clin Sci (Lond) 87(2): 143-9. 
 
Fahrner, T.J., Carroll, S.L. and Milbrandt, J. (1990).  Mol Cell Biol 10(12): 
6454-9. 
 
Feoktistov, I. and Biaggioni, I. (1995).  J Clin Invest 96(4): 1979-86. 
 
Feoktistov, I. and Biaggioni, I. (1998).  Biochem Pharmacol 55(5): 627-33. 
 
Feoktistov, I., Goldstein, A.E., Ryzhov, S., Zeng, D., Belardinelli, L., Voyno-
Yasenetskaya, T. and Biaggioni, I. (2002).  Circ Res 90(5): 531-8. 
 
Fischer, M., Harvima, I.T., Carvalho, R.F., Moller, C., Naukkarinen, A., 
Enblad, G. and Nilsson, G. (2006).  J Clin Invest 116(10): 2748-56. 
 
Fortin, A., Harbour, D., Fernandes, M., Borgeat, P. and Bourgoin, S. (2006).  J 
Leukoc Biol 79(3): 574-85. 
 
Fozard, J.R., Pfannkuche, H.J. and Schuurman, H.J. (1996).  Eur J 
Pharmacol 298(3): 293-7. 
 
Fredholm, B.B., Ijzerman, A.P., Jacobson, K.A., Klotz, K.-N. and Linden, J. 
(2001).  Pharmacol Rev 53(4): 527-552. 
 
Fredholm, B.B., Chern, Y., Franco, R. and Sitkovsky, M. (2007).  Progress in 
Neurobiology 83(5): 263. 
 
Gao, Z., Chen, T., Weber, M.J. and Linden, J. (1999).  J Biol Chem 274(9): 
5972-80. 
 
Garcia, G.E., Truong, L.D., Li, P., Zhang, P., Du, J., Chen, J.F. and Feng, L. 
(2008).  Faseb J 22(2): 445-54. 
 
Gessi, S., Varani, K., Merighi, S., Ongini, E. and Borea, P.A. (2000).  Br J 
Pharmacol 129(1): 2-11. 
 
 40 
Gessi, S., Varani, K., Merighi, S., Cattabriga, E., Avitabile, A., Gavioli, R., 
Fortini, C., Leung, E., Mac Lennan, S. and Borea, P.A. (2004).  Mol 
Pharmacol 65(3): 711-9. 
 
Glass, C.K. and Ogawa, S. (2006).  Nat Rev Immunol 6(1): 44-55. 
 
Hansen, P.B. and Schnermann, J. (2003).  Am J Physiol Renal Physiol 
285(4): F590-9. 
 
Harant, H. and Lindley, I.J. (2004).  Nucleic Acids Res 32(17): 5280-90. 
 
Harish, A., Hohana, G., Fishman, P., Arnon, O. and Bar-Yehuda, S. (2003).  
Int J Oncol 23(4): 1245-9. 
 
Hasko, G., Pacher, P., Deitch, E.A. and Vizi, E.S. (2007).  Pharmacol Ther 
113(2): 264-75. 
 
Heredia, A., Amoroso, A., Davis, C., Le, N., Reardon, E., Dominique, J.K., 
Klingebiel, E., Gallo, R.C. and Redfield, R.R. (2003).  Proc Natl Acad 
Sci U S A 100(18): 10411-6. 
 
Hirt, R.A., Vondrakova, K., de Arespacochaga, A.G., Gutl, A. and van den 
Hoven, R. (2007).  Vet J 173(1): 62-72. 
 
Hua, X., Chason, K.D., Fredholm, B.B., Deshpande, D.A., Penn, R.B. and 
Tilley, S.L. (2008).  J Allergy Clin Immunol 122(1): 107-13, 113 e1-7. 
 
Huszar, E., Vass, G., Vizi, E., Csoma, Z., Barat, E., Molnar Vilagos, G., 
Herjavecz, I. and Horvath, I. (2002).  Eur Respir J 20(6): 1393-8. 
 
Jacobson, K.A. and Gao, Z.G. (2006).  Nat Rev Drug Discov 5(3): 247-64. 
 
Khoa, N.D., Postow, M., Danielsson, J. and Cronstein, B.N. (2006).  Mol 
Pharmacol 69(4): 1311-9. 
 
Kohno, Y., Ji, X., Mawhorter, S.D., Koshiba, M. and Jacobson, K.A. (1996).  
Blood 88(9): 3569-74. 
 
Laemmli, U.K. (1970).  Nature 227(5259): 680-5. 
 
Lahiri, S., Mitchell, C.H., Reigada, D., Roy, A. and Cherniack, N.S. (2007).  
Respir Physiol Neurobiol 157(1): 123-9. 
 
Lammi, J., Rajalin, A.M., Huppunen, J. and Aarnisalo, P. (2007).  Biochem 
Biophys Res Commun 359(2): 391-7. 
 
Lappas, C.M., Rieger, J.M. and Linden, J. (2005).  J Immunol 174(2): 1073-
80. 
 
 41 
Lappas, C.M., Day, Y.J., Marshall, M.A., Engelhard, V.H. and Linden, J. 
(2006).  J Exp Med 203(12): 2639-48. 
 
Lee, D.M., Friend, D.S., Gurish, M.F., Benoist, C., Mathis, D. and Brenner, 
M.B. (2002).  Science 297(5587): 1689-92. 
 
Lee, H.T., Gallos, G., Nasr, S.H. and Emala, C.W. (2004).  J Am Soc Nephrol 
15(1): 102-11. 
 
Li, J., Fenton, R.A., Wheeler, H.B., Powell, C.C., Peyton, B.D., Cutler, B.S. 
and Dobson, J.G., Jr. (1998).  J Surg Res 80(2): 357-64. 
 
Liao, Y., Takashima, S., Asano, Y., Asakura, M., Ogai, A., Shintani, Y., 
Minamino, T., Asanuma, H., Sanada, S., Kim, J., Ogita, H., Tomoike, 
H., Hori, M. and Kitakaze, M. (2003).  Circ Res 93(8): 759-66. 
 
Linden, J. (2001).  Annu Rev Pharmacol Toxicol 41: 775-87. 
 
Martin, P.L. (1992).  Eur J Pharmacol 216(2): 235-42. 
 
McColl, S.R., St-Onge, M., Dussault, A.A., Laflamme, C., Bouchard, L., 
Boulanger, J. and Pouliot, M. (2006).  Faseb J 20(1): 187-9. 
 
McEvoy, A.N., Murphy, E.A., Ponnio, T., Conneely, O.M., Bresnihan, B., 
FitzGerald, O. and Murphy, E.P. (2002).  J Immunol 168(6): 2979-87. 
 
Merrill, J.T., Shen, C., Schreibman, D., Coffey, D., Zakharenko, O., Fisher, R., 
Lahita, R.G., Salmon, J. and Cronstein, B.N. (1997).  Arthritis Rheum 
40(7): 1308-15. 
 
Moro, S., Gao, Z.G., Jacobson, K.A. and Spalluto, G. (2006).  Med Res Rev 
26(2): 131-59. 
 
Ochaion, A., Bar-Yehuda, S., Cohn, S., Del Valle, L., Perez-Liz, G., Madi, L., 
Barer, F., Farbstein, M., Fishman-Furman, S., Reitblat, T., Reitblat, A., 
Amital, H., Levi, Y., Molad, Y., Mader, R., Tishler, M., Langevitz, P., 
Zabutti, A. and Fishman, P. (2006).  Arthritis Research & Therapy 8(6): 
R169. 
 
Ohta, A. and Sitkovsky, M. (2001).  Nature 414(6866): 916-20. 
 
Pagonopoulou, O., Efthimiadou, A., Asimakopoulos, B. and Nikolettos, N.K. 
(2006).  Neurosci Res 56(1): 14-20. 
 
Panther, E., Idzko, M., Herouy, Y., Rheinen, H., Gebicke-Haerter, P.J., 
Mrowietz, U., Dichmann, S. and Norgauer, J. (2001).  Faseb J 15(11): 
1963-70. 
 
Pei, L., Castrillo, A., Chen, M., Hoffmann, A. and Tontonoz, P. (2005).  J Biol 
Chem 280(32): 29256-62. 
 42 
 
Pei, L., Castrillo, A. and Tontonoz, P. (2006).  Mol Endocrinol 20(4): 786-94. 
 
Pei, L., Waki, H., Vaitheesvaran, B., Wilpitz, D.C., Kurland, I.J. and Tontonoz, 
P. (2006).  Nat Med 12(9): 1048-55. 
 
Ralph, J.A., McEvoy, A.N., Kane, D., Bresnihan, B., FitzGerald, O. and 
Murphy, E.P. (2005).  J Immunol 175(1): 555-65. 
 
Ribeiro, J.A. (2005).  Curr Drug Targets CNS Neurol Disord 4(4): 325-9. 
 
Ryzhov, S., Goldstein, A.E., Matafonov, A., Zeng, D., Biaggioni, I. and 
Feoktistov, I. (2004).  J Immunol 172(12): 7726-33. 
 
Ryzhov, S., Goldstein, A.E., Biaggioni, I. and Feoktistov, I. (2006).  Mol 
Pharmacol 70(2): 727-35. 
 
Salmon, J.E., Brogle, N., Brownlie, C., Edberg, J.C., Kimberly, R.P., Chen, 
B.X. and Erlanger, B.F. (1993).  J Immunol 151(5): 2775-85. 
 
Sawynok, J. and Liu, X.J. (2003).  Prog Neurobiol 69(5): 313-40. 
 
Schapira, A.H., Bezard, E., Brotchie, J., Calon, F., Collingridge, G.L., Ferger, 
B., Hengerer, B., Hirsch, E., Jenner, P., Le Novere, N., Obeso, J.A., 
Schwarzschild, M.A., Spampinato, U. and Davidai, G. (2006).  Nat Rev 
Drug Discov 5(10): 845-54. 
 
Schwarzschild, M.A., Agnati, L., Fuxe, K., Chen, J.F. and Morelli, M. (2006).  
Trends Neurosci 29(11): 647-54. 
 
Shepherd, R.K., Linden, J. and Duling, B.R. (1996).  Circ Res 78(4): 627-34. 
 
Shi, Y., Liu, X., Gebremedhin, D., Falck, J.R., Harder, D.R. and Koehler, R.C. 
(2008).  J Cereb Blood Flow Metab 28(1): 111-25. 
 
Silverman, M.H., Strand, V., Markovits, D., Nahir, M., Reitblat, T., Molad, Y., 
Rosner, I., Rozenbaum, M., Mader, R., Adawi, M., Caspi, D., Tishler, 
M., Langevitz, P., Rubinow, A., Friedman, J., Green, L., Tanay, A., 
Ochaion, A., Cohen, S., Kerns, W.D., Cohn, I., Fishman-Furman, S., 
Farbstein, M., Yehuda, S.B. and Fishman, P. (2008).  J Rheumatol 
35(1): 41-8. 
 
Sitaraman, S.V., Merlin, D., Wang, L., Wong, M., Gewirtz, A.T., Si-Tahar, M. 
and Madara, J.L. (2001).  J Clin Invest 107(7): 861-9. 
 
Sun, C.X., Young, H.W., Molina, J.G., Volmer, J.B., Schnermann, J. and 
Blackburn, M.R. (2005).  J Clin Invest 115(1): 35-43. 
 
 43 
Sun, C.X., Zhong, H., Mohsenin, A., Morschl, E., Chunn, J.L., Molina, J.G., 
Belardinelli, L., Zeng, D. and Blackburn, M.R. (2006).  J Clin Invest 
116(8): 2173-2182. 
 
Suzuki, H., Takei, M., Nakahata, T. and Fukamachi, H. (1998).  Biochem 
Biophys Res Commun 242(3): 697-702. 
 
Thiel, M., Chouker, A., Ohta, A., Jackson, E., Caldwell, C., Smith, P., 
Lukashev, D., Bittmann, I. and Sitkovsky, M.V. (2005).  PLoS Biol 3(6): 
e174. 
 
Trams, E.G. and Lauter, C.J. (1974).  Biochim Biophys Acta 345(2): 180-97. 
 
Tsutsui, S., Schnermann, J., Noorbakhsh, F., Henry, S., Yong, V.W., Winston, 
B.W., Warren, K. and Power, C. (2004).  J Neurosci 24(6): 1521-9. 
 
Van Belle, H., Goossens, F. and Wynants, J. (1987).  Am J Physiol Heart Circ 
Physiol 252(5): H886-893. 
 
Walker, B.A., Jacobson, M.A., Knight, D.A., Salvatore, C.A., Weir, T., Zhou, 
D. and Bai, T.R. (1997).  Am J Respir Cell Mol Biol 16(5): 531-7. 
 
Wallen-Mackenzie, A., Mata de Urquiza, A., Petersson, S., Rodriguez, F.J., 
Friling, S., Wagner, J., Ordentlich, P., Lengqvist, J., Heyman, R.A., 
Arenas, E. and Perlmann, T. (2003).  Genes Dev 17(24): 3036-47. 
 
Winoto, A. and Littman, D.R. (2002).  Cell 109 Suppl: S57-66. 
 
Young, H.W., Molina, J.G., Dimina, D., Zhong, H., Jacobson, M., Chan, L.N., 
Chan, T.S., Lee, J.J. and Blackburn, M.R. (2004).  J Immunol 173(2): 
1380-9. 
 
Zetterstrom, R.H., Solomin, L., Jansson, L., Hoffer, B.J., Olson, L. and 
Perlmann, T. (1997).  Science 276(5310): 248-50. 
 
Zhao, Y., Liu, Y. and Zheng, D. (2008).  Febs J 275(5): 1025-38. 
 
Zhong, H., Belardinelli, L., Maa, T., Feoktistov, I., Biaggioni, I. and Zeng, D. 
(2004).  Am J Respir Cell Mol Biol 30(1): 118-25. 
 
Zhong, H., Belardinelli, L., Maa, T. and Zeng, D. (2005).  Am J Respir Cell Mol 
Biol 32(1): 2-8. 
 
 
 44 
Zusammenfassung 
 
Adenosin ist ein paradoxer Entzündungsmodulator, der einerseits eine 
entzündungshemmende Wirkung haben kann und andererseits das 
Entzündungsgeschehen verlängern kann. In diesen Versuchen wurden mit 
Hilfe der Pharmakogenomik subtypen-spezifische Zellsignale der 
Adenosinsrezeptoren (AR) in der humanen Mastzelllinie-1 (HMC-1) 
identifiziert. Es wurden zwei Genprodukte, die bisher nicht mit Adenosin-
induzierter Zellvermittlung assoziiert wurden, genauer charakterisiert. Wir 
stellten fest, dass die AR-Aktivierung in einer Aufregulierung und Sekretion 
des ‚macrophage inflammatory protein-1 beta’ (MIP-1β) resultiert, was auf 
eine Adenosin-induzierte Modulierung der Chemotaxis über die Mastzellen 
schliessen lässt. Zudem konnten wir eine Aufregulierung der 
Transkriptionsfaktoren NR4A2 und NR4A3 beobachten. Dieser Effekt scheint 
von den AR Subtypen A2B und A3 vermittelt zu sein, wobei der AR-Subtyp A2A 
dieser Aktivierung entgegenwirkt. Darüber hinaus erkannten wir, dass eine 
nicht-selektive AR-Aktivierung die PMA/I-vermittelte Induktion der NR4A 
potentiert, während dem eine selektive Aktivierung des A2AAR dies teilweise 
rückgängig macht. Dies deutet darauf hin, dass der modulierende Effekt des 
A2AAR an andere proinflammatorische Stimuli gebunden sein muss. 
Insgesamt zeigen diese Ergebnisse, dass die AR-Aktivierung nicht nur über 
eine direkte Signalwirkung auf entzündungs-assoziierte Faktoren, sondern 
auch über die chemotaktische Rekrutierung von Entzündungszellen einen 
regulatorischen Effekt auf humane Mastzellen haben kann. 
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